Regarding “Perioperative Use of Statins Does not Reduce Cardiovascular Risk”  by Takagi, Hisato et al.
while the intimal lesions, frequently limited on the posterior wall,
play a minor role.
In our opinion, a transverse arteriotomy at the level of the
Angio-Seal introduction site could lead to a safe removal of the
anchorage system, permitting a sufficient exploration of the poste-
rior intimal layer.We retain that this has been the surgical approach
on patient 3 in this report. Moreover, in the case of a posterior
intimal defect, a limited resection of the flap and a Kunlin suture
can be performed easily. This approach is preferable, in our opin-
ion, allowing the avoidance of a longitudinal arteriotomy and
usage of a prosthetic patch for the arterial reconstruction. In our
experience, the longitudinal arteriotomy can be reserved only
where there is an extensive intimal lesion, previously demonstrated
by a transverse arteriotomy or in cases of diffuse atherosclerotic
involvement of the common femoral artery.
Moreover, if longitudinal arteriotomy is the only option, we
suggest the use of an autologous saphenous vein patch to decrease
the possibility of infection as demonstrated by Gonzo et al.3-5
In conclusion, we believe the ischemic complication of the
Angio-Seal device should be approached by a transverse arteriot-
omy, without the use of prosthetic material. An eventual autolo-
gous vein patch is the preferred material when an arterial recon-
struction is needed.
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Reply
There is no scientific evidence to prefer either the transverse or
longitudinal arteriotomy for removal of endoluminally displaced
Angio-Seal sponges. We elected to use longitudinal arteriotomies
in all four patients who were the subjects of our report because
longitudinal arteriotomy provides better intraluminal exposure. In
three of the patients, the arteriotomy was closed without patch
insertion. Intraluminal displacement of Angio-Seal sponges often
is due to plaque. A longitudinal arteriotomy provides better expo-
sure and allows a more controlled removal of a plaque that pro-
trudes or that is partially avulsed due to interference with the
Angio-Seal device.
Although closure of longitudinal arteriotomy may produce
stenosis, which may be prevented by closure with a patch, it has
been shown experimentally that it is possible to close longitudinal
arteriotomies without creating significant stenosis even in thin rat
femoral arteries.1 In our experience, longitudinal arteriotomies
usually can be closed without creating a stenosis and without the
necessity of using a patch provided small bites are taken with the
suture and provided the suture is not tightened unnecessarily.
Whenever possible, it is desirable to avoid using prosthetic
material when an arteriotomy is being closed, and particularly in
the groin, because of the risk of infection and the prosthetic
material’s tendency to provoke foreign body reaction and throm-
bus formation. In the groin, a minor stenosis due to direct closure
without a patch may be preferable to patch closure due to the risk
of infection. When a patch has to be used, a vein patch is preferable
to a prosthetic patch,2-4 and it should not be so wide as to cause a
marked increase in luminal diameter at the arteriotomy site since a
localized arterial widening can cause turbulence and mural throm-
bus formation.5
Einar Dregelid, MD
Vascular Section, Department of Surgery
Haukeland University Hospital
Bergen, Norway
REFERENCES
1. Cipoletti RD, Moneim MS, Greene ER. Hemodynamic comparison of
microsurgical closures for longitudinal arteriotomies. Microsurgery
1993;14:107-13.
2. Archie JP Jr. Restenosis after carotid endarterectomy in patients with
paired vein and Dacron patch reconstruction. Vasc Surg 2001;35:
419-27.
3. Archie JP. Carotid endarterectomy outcome with vein or Dacron graft
patch angioplasty and internal carotid artery shortening. J Vasc Surg
1999;29:654-64.
4. Verhoeven BA, Pasterkamp G, de Vries JP, Ackerstaff RG, de Kleijn D,
Eikelboom BC, et al. Closure of the arteriotomy after carotid endarter-
ectomy: patch type is related to intraoperative microemboli and resteno-
sis rate. J Vasc Surg 2005;42:1082-8.
5. Johnson BL, Gupta AK, Bandyk DF, Shulman C, Jackson M. Anatomic
patterns of carotid endarterectomy healing. Am J Surg 1996;172:
188-90.
doi:10.1016/j.jvs.2007.04.055
Regarding “Perioperative Use of Statins Does not
Reduce Cardiovascular Risk”
In the article by Schouten et al,1 the authors included the
review of several recent studies that addressed the beneficial effect
of statin use in patients undergoing “major vascular, noncardiac
surgery.”
Soon after the publication of the article by Schouten et al
(August 2006),1 a systematic review by Kapoor et al2 to determine
the strength of evidence for using statins during the perioperative
period to reduce the risk of cardiovascular events was pub-
lished (November 2006). Owing to methodological heterogeneity
among studies, they carried out a meta-analysis of methodologi-
cally similar studies (eg, all randomized trials or all cohort studies).
Regarding perioperative death or acute coronary syndrome, pool-
ing the data from all 13 cohort studies gave a summary odds ratio
(OR) of 0.70 (95% confidence interval [CI], 0.57 to 0.87) with
statin use (1, favors statin use; 1, favors control). Certainly,
these 13 studies were methodologically similar because of all
cohorts. Obvious between-study heterogeneity concerning types
of surgery, however, was present in the pooled estimate derived
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from these 13 cohort studies. The 13 studies pooled by Kapoor
et al2 included both 10 cohorts of “noncardiac surgery” and three
cohorts of “cardiac surgery.” The pooled OR from the 10 studies
of “noncardiac surgery” was 0.70 (95% CI, 0.53 to 0.91). Further-
more, these 10 cohorts of “noncardiac surgery” included six
studies of “major (noncarotid) vascular, noncardiac surgery” (eg,
repair of abdominal aortic aneurysm, aorto-femoral bypass, and
infrainguinal revascularization), two studies of “carotid endarter-
ectomy,” one study of both “carotid endarterectomy” and “major
(noncarotid) vascular, noncardiac surgery,” and one study of “tho-
racic surgery.”
We combined the data from the above-mentioned homoge-
nous six cohort studies3-8 of “major (noncarotid) vascular, noncar-
diac surgery” (380 events in 4865 patients) using a random-effects
model, which gave a summary OR of 0.74 (95% CI, 0.54 to 1.01;
P .0590) with statin use. There was neither trial heterogeneity of
results analyzed by means of standard 2 tests (P  .2602) nor
evidence of significant publication bias assessed using an adjusted
rank-correlation test (P  .8510). Therefore, routine administra-
tion of statins does not reduce perioperative cardiovascular risk in
“major (noncarotid) vascular, noncardiac surgery.”
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We appreciate the interest of Dr Takagi and colleagues regard-
ing our publication “Statins for the prevention of perioperative
cardiovascular complications in vascular surgery”.
First, we would like to point out that the only double blind
randomized trial published so far that specifically investigated the
effect of statins on perioperative cardiovascular outcome showed a
significant beneficial effect of perioperative statin use (8% vs 26%
cardiovascular complications, P  .03).1
Second, why did Dr Takagi and colleagues only use six retro-
spective studies for their analysis? We agree that including studies
reporting on carotid surgery only2 in their systematic review would
be incorrect. However, the study by O’Neil-Callahan et al3 should
have been included in their review since this study included 177
aortic and 622 lower extremity arterial surgical procedures. If these
799 patients would have been added to the analysis of Takagi and
colleagues, the odds ratio would be 0.71 with 95% confidence
intervals of 0.57 to 0.88 and P for homogeneity of .313. This
suggests a beta-II error of the presented analysis byDr Takagi. If all
appropriate studies were taken into account, statins would have
provided a highly significant beneficial effect on postoperative
outcome in patients undergoing major vascular surgery.
Third, current American College of Cardiology/American
Heart Association (ACC/AHA) treatment guidelines recommend
statin use for patients at increased cardiovascular risk.4 In fact these
guidelines have as a class 1 recommendation “treatment with a
hydroxymethyl glutaryl coenzyme-A reductase inhibitor medica-
tion is indicated for all patients with peripheral arterial disease to
achieve a target low-density lipoprotein (LDL) cholesterol level of
less than 100 mg per dl.” As all patients scheduled for major
vascular surgery have peripheral arterial disease, it would be pru-
dent to install treatment at the first vascular surgery outpatient
clinic visit. In particular, since current evidence does suggest that
there is no increased risk for myopathy or rhabdomyolysis in
patients on statin therapy undergoing major vascular surgery.5
In conclusion, if a proper meta-analysis of all cohort studies
reporting on cardiac outcome in statin or nonstatin users under-
going major vascular surgery is performed, the results show a
highly significant beneficial effect of statins. This result is sup-
ported by the only double blind randomized trial published on this
subject to date. Consequently, we still believe that routine admin-
istration of statins in patients undergoing major vascular surgery
reduces perioperative cardiovascular risk.
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